Oracle’s 3rd Annual Drug Development and Safety Forum 2009- India


Oracle’s 3rd Annual Drug Development and Safety Forum 2009

October 21 – 22, 2009

Oracle invites you to the 2009 Drug Development and Safety Forum

At this forum we will be discussing important topics and issues facing the Indian Pharmaceutical Biotechnology, and CRO industry. This event will be highlighted by presentations from key industry thought leaders who will share their perspective on industry best practices as well as their unique experiences.

The content will cover important topics in clinical development, and safety. You will hear how Oracle solutions have enabled organizations in the industry shorten their time to market, gain operational efficiencies, reduce clinical study costs and accelerate insight into action

As a follow up to the success of last two year’s Clinical Development and Safety Forum this year’s event will prove to be a must attend event.

October 21 – 22, 2009

The Leela Kempinski
Sahar, Mumbai, India

To Register Now , contact Sushma at +91 80 4029 1295 (include your name, company, e-mail address, contact mobile number, arrival/departure – dates/time).

•    Keynote Presentations
•    Networking lunch
•    Networking Dinner on the first day
•    Perspectives from industry strategists and thought leaders
•    Hear about business best practices and lessons learned from leading companies
•    A unique networking opportunity with colleagues, industry and Oracle experts

Oracle and Inforsense Integrating Clinical And Genomics Data for Personalized Medicine


The March-April 2009 issue of Bio-IT World features Dana-Farber Cancer Institute cover story on integrating clinical and genomics data including details on the organization’s work with Oracle and InforSense, as well as a byline article on platforms for personalized medicine by Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences.

Integrating Clinical and Genomics Data

The cover story of Bio-IT World highlights the groundbreaking work of Dana-Farber Cancer Institute’s (DFCI) John Quackenbush, professor of biostatistics and computational biology, who at the vanguard of translational medicine is bridging genomics, bioinformatics, and IT in an effort to shed light on cancer biology. With assists from Oracle and InforSense, Dana-Farber’s John Quackenbush is finding ways to mine vast patient data collections to better understand human cancer. “Our successful collaboration with Oracle and InforSense has put us in a position to think about reaching beyond DFCI and gradually pulling in a lot of Harvard’s multi-institutional spores and their data collections,” Quackenbush says.

To read the complete Bio-IT World cover story article on integrating clinical and genomics data, click here.

Platforms for Personalized Medicine
This article by Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences discusses personalized medicine and how integrating clinical information and R&D data can ensure success. Personalized medicine promises to improve understanding of the mechanisms of disease and permit more effective patient care. It also stands to transform the focus of the pharmaceutical industry as the cost of drug discovery exceeds $1 billion, and established blockbuster drugs lose patent protection. Although it holds great promise, realizing the benefits of personalized medicine presents significant challenges for life sciences companies, particularly surrounding the integration of research and clinical data – both within and between life sciences companies and healthcare organizations.
To read the complete Bio-IT World article on platforms for personalized medicine, click here.

Oracle announced it agreed to acquire Relsys

On March 23, 2009, Oracle announced it agreed to acquire Relsys, a leading provider of drug safety, risk management and analytics applications for the health sciences industry. Relsys’s best-in-class solutions support adverse event reporting, risk management and drug safety analysis for pharmaceutical, biotechnology, contract research organizations and medical device companies worldwide.

More details on Oracle website:

%d bloggers like this: